Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations

References

• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive sig-nalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013;369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391–2405.
   PubMed Web of Science ®Google Scholar
• Zamanian M, Veerakumarasivam A, Abdullah S, et al. Calreticulin and cancer. Pathol Oncol Res 2013;19:149–154.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Zuppini A, Arnaudeau S, et al. Functional specialization of calreticulin domains. J Cell Biol 2001;154:961–972.
   PubMed Web of Science ®Google Scholar
• Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol 2012;44:842–846.
   PubMed Web of Science ®Google Scholar
• Pocanschi CL, Kozlov G, Brockmeier U, et al. Structural and functional relationships between the lectin and arm domains of calreticulin. J Biol Chem 2011;286:27266–27277.
   PubMed Web of Science ®Google Scholar
• Michalak M, Corbett EF, Mesaeli N, et al. Calreticulin: one protein, one gene, manyfunctions. Biochem J 1999;344:281–292.
   PubMed Web of Science ®Google Scholar
• Michalak M, Groenendyk J, Szabo E, et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009;417:651–666.
   PubMed Web of Science ®Google Scholar
• Goicoechea S, Pallero MA, Eggleton P, et al. The anti-adhesive activity of thrombospondin is mediated by the N- terminal domain of cell surface calreticulin. J Biol Chem 2002;277:37219–37228.
   PubMed Web of Science ®Google Scholar
• Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24:665–683.
   PubMed Web of Science ®Google Scholar
• Molinari M, Eriksson KK, Calanca V, et al. Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control. Mol Cell 2004;13:125–135.
   PubMed Web of Science ®Google Scholar
• Gao B, Adhikari R, Howarth M, et al. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunology 2002;16:99–109.
   Google Scholar
• Szabo E, Qui Y, Baksh S, et al. Calreticulin inhibits commitment to adipocyte differentiation. J Cell Biol 2008;182:103–116.
   PubMed Web of Science ®Google Scholar
• Bibi A, Agarwal NK, Dihazi GH, et al. Calreticulin is crucial for calcium homeostasis mediated adaptation and survival of thick ascending limb of Henle's loop cells under osmotic stress. Int J Biochem Cell B 2011;43:1187–1197.
   PubMed Web of Science ®Google Scholar
• Nanney LB, Woodrell CD, Greives MR, et al. Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol 2008;173:610–630.
   PubMed Web of Science ®Google Scholar
• Chaput N, Botton SD, Obeid M, et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 2007;85:1069–1076.
   PubMed Web of Science ®Google Scholar
• Wemeau M, Kepp O, Tesnière A, et al. Cal-reticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010;1:1–9.
   Web of Science ®Google Scholar
• Shaffer KL, Sharma A, Snapp EL, et al. Regulation of protein compartmentalization expands the diversity of protein function. Dev Cell 2005;9:545–554.
   PubMed Web of Science ®Google Scholar
• Waser M, Mesaeli N, Spencer C, et al. Regulation of calreticulin gene expression by calcium. J Cell Biol 1997;138:547–557.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Lynch J, Guo L, et al. Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors. Biochemistry 2008;47:3697–3704.
   PubMed Web of Science ®Google Scholar
• Vig S, Pandey AK, Verma G, et al. C/EBPα mediates the transcriptional suppression of human calreticulin gene expression by TNFα. Int J Cell Biol 2012;44:113–122.
   Web of Science ®Google Scholar
• Villamil Giraldo AM, Lopez Medus M, Gonzalez Lebrero M, et al. The structure of calreticulin C-terminal domain is modulated by physiological variations of calcium concentration. J Biol Chem 2010;285:4544–4553.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012;12:860–875.
   PubMed Web of Science ®Google Scholar
• Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013;32:805–818.
   PubMed Web of Science ®Google Scholar
• Helbling D, Mueller BU, Timchenko NA, et al. CBFB-SMM HC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 2005;106:1369–1375.
   PubMed Web of Science ®Google Scholar
• Schardt JA, Eyholzer M, Timchenko NA, et al. Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia. J Cell Mol Med 2010;14:1509–1519.
   PubMed Web of Science ®Google Scholar
• Chen CN, Chang CC, Su TE, et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 2009;16:524 –533.
   PubMed Web of Science ®Google Scholar
• Lwin ZM, Guo C, Salim A, et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol 2010;23:1559–1566.
   PubMed Web of Science ®Google Scholar
• Du XL, Yang H, Liu SG, et al. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 2009; 28:3714–3722.
   Google Scholar
• Pallero MA, Elzie CA, Chen J, et al. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008;22: 3968–3979.
   PubMed Web of Science ®Google Scholar
• Lusche DF, Wessels D, Soll DR. The effects of extracellular calcium on motility, pseudopod and uropod formation, chemotaxis, and the cortical localization of myosin II in Dictyostelium discoideum. Cell Motil Cytoskeleton 2009;66:567–587.
   PubMed Web of Science ®Google Scholar
• Chantome A, Girault A, Potier M, et al. KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 2009;315:3620–3630.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723–1735.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128–1138.
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686–1689.
   PubMed Web of Science ®Google Scholar
• Boyd EM, Bench AJ, Goday-Fernandez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010;149:250–257.
   PubMed Web of Science ®Google Scholar
• Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010;363:1189–1190.
   PubMed Web of Science ®Google Scholar
• Spolverini A, Pieri L, Guglielmelli P, et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative “idiopathic” erythrocytosis. Haematologica 2013;98:e101–e102.
   Google Scholar
• Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123: 1552–1555.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123:1544–1551.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120: 1197–1201.
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169–175.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472–1477.
   PubMed Web of Science ®Google Scholar
• Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia 2014;28:1552–1555.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28:1494–1500.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28:1568–1570.
   PubMed Web of Science ®Google Scholar
• Chi J, Nicolaou KA, Nicolaidou V, et al. Calreticulin gene exon 9 frameshiftmutations in patients with thrombocytosis. Leukemia 2014;28:1152–1154.
   PubMed Web of Science ®Google Scholar
• Lynch J, Michalak M. Calreticulin is an upstream regulator of calcineurin. Biochem Biophys Res Commun 2003;311:1173–1179.
   PubMed Web of Science ®Google Scholar
• Fric J, Lim CX, Koh EG, et al. Calcineurin/NFAT signalling inhibits myeloid haematopoiesis. EMBO Mol Med 2012;4:269–282.
   PubMed Web of Science ®Google Scholar
• Zaslavsky A, Chou ST, Schadler K, et al. The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood 2013;121: 3205–3215.
   PubMed Web of Science ®Google Scholar
• Guo L, Nakamura K, Lynch J, et al. Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse. J Biol Chem 2002;277:50776–50779.
   PubMed Web of Science ®Google Scholar
• Guo GG, Patel K, Kumar V, et al. Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J Interferon Cytokine Res 2002;22:555–563.
   PubMed Web of Science ®Google Scholar
• Eufemi M, Coppari S, Altieri F, et al. ERp57 is present in STAT3-DNA complexes. Biochem Biophys Res Commun 2004;323:1306–1312.
   Google Scholar
• Coe H, Jung J, Groenendyk J, et al. ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J Biol Chem 2010;285:6725–6738.
   PubMedGoogle Scholar